Mankind Pharma Q4 FY26: Margin rebound, chronic mix gains, and steadier cash conversion

Mankind Pharma ended Q4 FY26 with revenue from operations of INR 3,443 crore, up 11.8 percent year on year. Profitability strengthened sharply in the quarter. EBITDA rose to INR 910 crore, up 32.7 percent, taking reported EBITDA margin to 26.4 percent. Adjusted EBITDA was INR 933 crore, implying an adjusted margin of 27.1 percent, after adjusting for one-time impact of labour code regulations and other non-recurring costs. Profit after tax increased 30.4 percent year on year to INR 559 crore, and diluted EPS for the quarter came in at INR 13.4.

The quarter matters because it shows how the portfolio is settling into a new shape after the integration of BSV and the continued push toward specialty chronic therapies. Management commentary framed the strategy around four pillars: a steady base domestic business, a faster-growing specialty chronic engine, a higher-potential consumer healthcare portfolio, and a super specialty BSV franchise with high entry barriers. The quarter’s numbers show progress on all four, even as international growth stayed muted due to geopolitical headwinds.

Q4 performance: domestic strength, OTC momentum, and export headwinds

In Q4 FY26, domestic business revenue was INR 2,886 crore, up 13.4 percent year on year. Within this, domestic business excluding consumer healthcare grew 12.9 percent to INR 2,673 crore. Consumer healthcare grew faster, rising 19.8 percent to INR 213 crore. Exports were the soft spot. International business grew 4.2 percent to INR 557 crore in the quarter.

Management highlighted that domestic growth was led by double-digit performance in the core Mankind portfolio and strong contribution from the BSV specialty business. Chronic therapies remained an anchor. Cardiac grew 14.7 percent and anti-diabetes grew 11.6 percent in Q4 FY26, along with a 120 basis point year-on-year increase in chronic share to around 40 percent. Acute therapies were mixed, with a sequential recovery reported in gastro, VMN, and other areas, while anti-infectives saw muted growth.

Consumer healthcare continued to show improving execution, helped by e-commerce and modern trade. Management noted that OTC business grew 20 percent, supported by strong growth in e-commerce. In exports, the company cited geopolitical headwinds as the key driver behind muted quarterly growth.

Mix shift inside India: chronic share rises as brands scale

The domestic business remains the core of the story. India contributed 86 percent of FY26 revenue, and domestic revenue reached INR 12,217 crore for the year, up 14 percent. This is supported by a large field force of more than 18,500 people as of March 2026, a doctor coverage of 5 lakh, and a distribution network of over 12,000 stockists.

A key theme through the presentation was the steady increase in chronic contribution. For Mankind excluding BSV, chronic share rose from 36.6 percent in FY25 to 38.5 percent in FY26, and from 38.7 percent in Q4 FY25 to 39.9 percent in Q4 FY26. On a consolidated basis, chronic share increased from 35.4 percent in FY25 to 37.0 percent in FY26.

The chronic shift is not just mix; it is also supported by targeted launches and portfolio moves. The presentation pointed to outperformance versus the Indian pharmaceutical market in FY26 in cardiac and anti-diabetic therapies, and highlighted growth in inhalers through Combihale and Symbicort, growth in Nobeglar (insulin glargine), and the strong prescription position of Crenzlo.

Brand scaling is another visible pattern. By FY26, the company had three brand families above INR 500 crore: Telmikind at INR 783 crore, Nurokind at INR 667 crore, and Manforce at INR 647 crore. It also expanded the base of brands above INR 200 crore, INR 100 crore, and INR 50 crore, and added several brands above INR 50 crore in FY26 such as Lactare, D3 Must, Statpure, Mahaflox, and Ossopan.

The therapy-wise table in the presentation also reinforces the breadth of the domestic franchise. In Q4 FY26, Mankind ranked first in gynaecology with 11 percent market share, and held high ranks across chronic and acute therapies. At an overall level, it ranked second with 4.7 percent market share.

Consumer healthcare and exports: one scaling, one stabilising

Consumer healthcare is still a smaller share of the domestic base, but it is behaving like a growth lever. FY26 consumer healthcare revenue was INR 879 crore, up 8.7 percent year on year. The more important signal is the Q4 acceleration to 20 percent growth and improving channel mix. Modern trade and e-commerce share rose to 13 percent in FY26 from 9 percent in FY25, supported by 57 percent growth.

The segment’s adjusted EBITDA margin trend in the presentation shows a gradual improvement into Q4 FY26, when adjusted EBITDA margin was 21.4 percent. The company attributed Q4 growth to strong performance in brands such as Manforce, Prega News, Gasofast, and Nimulid.

Exports remain structurally important, but volatile in the short run. FY26 export revenue increased 34.5 percent to INR 2,061 crore, following sharp growth in FY24 and FY25. But Q4 FY26 grew only 4 percent year on year to INR 557 crore due to geopolitical headwinds. The company also noted that Mankind excluding BSV launched four new products in FY26, taking total launched products in the US to 48.

Cash, capital efficiency, and the balance sheet trajectory

Beyond growth, FY26 showed continued focus on cash generation and deleveraging after the BSV acquisition. Cash flow from operations rose to INR 3,121 crore in FY26, up from INR 2,413 crore in FY25. The CFO to EBITDA ratio remained high across the last three years, with quarterly and annual data suggesting cash conversion around the 80 to 90 percent range.

Capex increased to INR 737 crore in FY26 from INR 531 crore in FY25, with capex as a percentage of revenue rising to 5.2 percent. This indicates that the company is investing into its manufacturing and growth priorities while still maintaining cash generation.

Net debt reduced to INR 3,932 crore as of March 31, 2026, improving from INR 5,784 crore as of March 31, 2025. Net debt to EBITDA improved steadily to 1.1x by the end of FY26. Working capital discipline also held up, with net operating working capital days at 43 as of March 31, 2026, compared with 45 at March 31, 2025.

On capital efficiency, the presentation reported ROCE at 41 percent on a trailing twelve-month basis with the BSV acquisition impact included, and 12 percent as the base metric shown alongside. The company also presented adjusted ROCE at 41 percent, excluding the acquisition impact, based on its stated methodology.

This combination of improving leverage, disciplined working capital, and sustained cash conversion is important for the next phase of strategy. It gives the company capacity to support specialty launches, strengthen consumer healthcare, and continue building the super specialty platform.

Strategy signals: deeper chronic, more specialty, and broader channels

The strategy section of the presentation lays out a clear roadmap. The company wants to consolidate market share in covered markets, raise chronic share further, expand toward super specialty through M and A and in-licensing, increase penetration in metros and tier 1 cities, grow consumer healthcare via Rx to OTx to OTC pathways, and raise focus on R and D by leveraging the BSV technology platform.

The portfolio examples in the presentation show how this strategy is being operationalised. In cardiac, Neptaz (in-licensed from Novartis) targets heart failure, while Crenzlo (also in-licensed from Novartis) positions Mankind in lipid-lowering injectables through inclisiran. In respiratory, the company is building around Combihale and Symbicort through an exclusive distribution agreement with AstraZeneca for India. In anti-diabetes, it entered niche insulin through Nobeglir in-licensed from Biocon. In gastro, it in-licensed vonoprazan from Takeda through Vonatime and Vonalong. In FY26, it acquired Rivotril in CNS from Roche.

These moves matter because they shift the business from a pure volume-led mass market model to one that also participates in premium, specialist-led categories. That can improve durability of growth and support margins, but it also requires sustained execution in specialist coverage, hospital engagement, and supply reliability.

What to watch from here

Q4 FY26 showed that Mankind can deliver double-digit revenue growth while expanding margins, supported by domestic execution and a sharper chronic mix. The quarter also showed the different speeds within the portfolio: consumer healthcare is gaining pace, exports are growing over the year but faced a softer quarter, and the super specialty addition is being positioned as a long-duration advantage.

For investors, the cleanest signals in the presentation are the improving profitability in Q4, the steady rise in chronic share, and the balance sheet trend as net debt to EBITDA moved to 1.1x by March 2026. The company’s forward plan is consistent with what the numbers already show: more specialty and super specialty depth, broader channels in consumer healthcare, and stronger metro presence. If execution holds, FY26’s mix improvements and cash conversion can provide a stable base for the next phase of growth.